Ironwood and Allergan settle Linzess patent infringement suit with Sun Pharma

|About: Allergan plc (AGN)|By:, SA News Editor

Ironwood Pharmaceuticals (IRWD +0.5%) and commercialization partner Allergan (AGN +1.1%) have settled their patent infringement litigation with generic drug maker Sun Pharmaceuticals related to its U.S. marketing application seeking approval for a generic version of constipation med LINZESS (linaclotide).

Under the terms of the settlement, Sun subsidiaries will be granted a license to market a generic product beginning on February 1, 2031 or earlier under certain circumstances.

Patent infringement suits against other would-be competitors remain pending.

Subscribe for full text news in your inbox